GLAXO.BO

GlaxoSmithKline Pharmaceuticals Limited is a prominent pharmaceutical company involved in the manufacturing, distribution, and sale of medicines across India and internationally. Its extensive product portfolio includes a range of vital vaccines: Infanrix Hexa, for infant protection against six diseases including diphtheria, tetanus, and hepatitis B; Synflorix, for pneumococcal infections and acute otitis media; Havrix, preventing Hepatitis A; Menveo, targeting invasive meningococcal disease; Boostrix, for diphtheria, tetanus, and pertussis; Fluarix Tetra, for influenza prevention; Varilrix, for active immunization against varicella; and Shingrix, designed to prevent Shingles and post-herpetic neuralgia. The company also offers specialty medications such as NUCALA, for severe eosinophilic asthma, and TRELEGY ELLIPTA, used in the treatment of chronic obstructive pulmonary disease. Its general medicine division provides a broad spectrum of products, including essential antibiotics like AUGMENTIN and CEFTUM for bacterial infections, and Supacef, a bactericidal cephalosporin. Other offerings include CALPOL for pain relief, ELTROXIN for hypothyroidism, CCM for calcium and vitamin D deficiency, and various dermatological treatments such as NEOSPORIN, BETNOVATE, T-BACT, TENOVATE, Flutivate, and Zimig for bacterial, inflammatory, and fungal skin conditions, alongside PHYSIOGEL for dry skin. Additionally, it supplies COBADEX CZS, a multivitamin. Beyond its current offerings, GlaxoSmithKline actively develops new products, with a focus on infectious diseases, HIV, oncology, and immunology. The company, originally incorporated in 1924 as SmithKline Beecham Pharmaceuticals India Ltd., adopted its current name in 2001 and is headquartered in Mumbai, India.